Rizwan Parvaiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rizwan Parvaiz has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alberte Cathrine Ehrhardt Jeppesen
VIRTU Research Group, Mental Health Center Copenhagen, Copenhagen University Hospital - Mental Health Services CPH, Gentofte Hospitalsvej 3A, 4th Floor, Copenhagen, 2900, Denmark, +45 21452889
2 shared publications - Amy Elizabeth Pinkham
University of Texas at Dallas
2 shared publications - Anne Sofie Due
VIRTU Research Group, Mental Health Center Copenhagen, Copenhagen University Hospital - Mental Health Services CPH, Gentofte Hospitalsvej 3A, 4th Floor, Copenhagen, 2900, Denmark, +45 21452889
2 shared publications - Carsten Hjorthøj
EMPIRA, Copenhagen Research Center for Mental Health‐CORE Bispebjerg and Frederiksberg Hospital Copenhagen Denmark
2 shared publications - Jens Richardt Møllegaard Jepsen
Copenhagen Research Center for Mental Health Copenhagen University Hospital, Capital Region of Denmark Copenhagen Denmark
2 shared publications - Johannes Andresen
VIRTU Research Group, Mental Health Center Copenhagen, Copenhagen University Hospital - Mental Health Services CPH, Gentofte Hospitalsvej 3A, 4th Floor, Copenhagen, 2900, Denmark, +45 21452889
2 shared publications
Latest Publications
- Open Access
- 5 January 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e72854
The Effect of Virtual Reality–Based Social Cognitive Training for Autistic Adults: Protocol for STEPS (Social Cognitive Training Enhancing Pro-Functional Skills) Randomized Clinical Trial
Background: Autistic adults constitute a growing and largely overlooked population with limited clinical and research resources. Social cognitive impairments are key deficits faced by this population, significantly impacting social interactions, educational and vocational functioning, and quality of life. Interventions targeting social cognition in autistic adults have shown promising results. Recent studies investigating the effect of virtual reality (VR)–based interventions for autistic adults have provided preliminary evidence supporting the feasibility and effectiveness of using this innovative technology. These studies indicate that VR interventions can enhance functional and social skills and improve specific neurocognitive and social cognitive functions. However, large-scale randomized clinical trials are urgently needed to fully assess the effectiveness of VR-based interventions for autistic adults. Objective: This protocol aims to provide a comprehensive description of the design and methodology of the STEPS (Social Cognitive Training Enhancing Pro-Functional Skills) trial. Methods: STEPS is a clinical, randomized, assessor-blinded, parallel-group superiority trial. A total of 140 participants will be allocated to receive either virtual reality–based social cognitive training (VRSCT) + treatment as usual (TAU) or TAU alone. The experimental group will receive 12 weekly 1-hour sessions of VRSCT, aiming at improving psychosocial functioning and social cognition through exposure to virtual social environments. The intervention comprises 3 core modules, namely emotions, social understanding, and complex social interactions. The exact content and duration of TAU received by each participant will be mapped and documented upon trial completion. Assessments will be conducted at baseline, at cessation of the intervention (3 months post baseline), and at 6 months post baseline. Results: Participant enrollment began in May 2024. As of February 2025 (initial manuscript submission), 34 participants had been enrolled, increasing to 97 participants as of December 2025. Completion of enrollment is expected in April 2026. Data analysis is expected to begin in October 2026 following the final 6-month follow-up assessment. Results are anticipated in December 2026 and will be disseminated through peer-reviewed publications. Conclusions: To our knowledge, STEPS is the hitherto largest randomized clinical trial globally investigating the effect of VRSCT for autistic adults. The results of this innovative intervention approach may significantly advance research in the field of autism. VRSCT holds potential to improve psychosocial functioning, quality of life, and co-occurring clinical symptoms, and to reduce social cognitive deficits in autistic adults. Establishing evidence-based interventions is crucial for addressing the debilitating psychosocial challenges faced by this population, especially considering the absence of established gold-standard treatments.
- 5 January 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e72854
Open AccessThe Effect of Virtual Reality–Based Social Cognitive Training for Autistic Adults: Protocol for STEPS (Social Cognitive Training Enhancing Pro-Functional Skills) Randomized Clinical Trial
Background: Autistic adults constitute a growing and largely overlooked population with limited clinical and research resources. Social cognitive impairments are key deficits faced by this population, significantly impacting social interactions, educational and vocational functioning, and quality of life. Interventions targeting social cognition in autistic adults have shown promising results. Recent studies investigating the effect of virtual reality (VR)–based interventions for autistic adults have provided preliminary evidence supporting the feasibility and effectiveness of using this innovative technology. These studies indicate that VR interventions can enhance functional and social skills and improve specific neurocognitive and social cognitive functions. However, large-scale randomized clinical trials are urgently needed to fully assess the effectiveness of VR-based interventions for autistic adults. Objective: This protocol aims to provide a comprehensive description of the design and methodology of the STEPS (Social Cognitive Training Enhancing Pro-Functional Skills) trial. Methods: STEPS is a clinical, randomized, assessor-blinded, parallel-group superiority trial. A total of 140 participants will be allocated to receive either virtual reality–based social cognitive training (VRSCT) + treatment as usual (TAU) or TAU alone. The experimental group will receive 12 weekly 1-hour sessions of VRSCT, aiming at improving psychosocial functioning and social cognition through exposure to virtual social environments. The intervention comprises 3 core modules, namely emotions, social understanding, and complex social interactions. The exact content and duration of TAU received by each participant will be mapped and documented upon trial completion. Assessments will be conducted at baseline, at cessation of the intervention (3 months post baseline), and at 6 months post baseline. Results: Participant enrollment began in May 2024. As of February 2025 (initial manuscript submission), 34 participants had been enrolled, increasing to 97 participants as of December 2025. Completion of enrollment is expected in April 2026. Data analysis is expected to begin in October 2026 following the final 6-month follow-up assessment. Results are anticipated in December 2026 and will be disseminated through peer-reviewed publications. Conclusions: To our knowledge, STEPS is the hitherto largest randomized clinical trial globally investigating the effect of VRSCT for autistic adults. The results of this innovative intervention approach may significantly advance research in the field of autism. VRSCT holds potential to improve psychosocial functioning, quality of life, and co-occurring clinical symptoms, and to reduce social cognitive deficits in autistic adults. Establishing evidence-based interventions is crucial for addressing the debilitating psychosocial challenges faced by this population, especially considering the absence of established gold-standard treatments.
- Open Access
- 21 February 2025
- Published by JMIR Publications Inc. in JMIR Preprints
The Effect of Virtual Reality-based Social Cognitive Training for Autistic Adults: A Study Protocol for STEPS (Social Cognitive Training Enhancing Pro-functional Skills), a Randomised Clinical Trial (Preprint)
BACKGROUND Autistic adults (AA) constitute a growing and largely overlooked population with limited clinical and research resources. Social cognitive impairments are key deficits faced by this population, significantly impacting social interactions, educational and vocational functioning, and quality of life. Interventions targeting social cognition in AA, have shown promising results. Recent studies investigating the effect of virtual reality (VR)-based interventions for AA have provided preliminary evidence supporting the feasibility and effectiveness of utilizing this innovative technology. These studies indicate that VR-interventions can enhance functional and social skills and improve specific neurocognitive and social cognitive functions. However, large scale, randomised, clinical trials are urgently needed to fully assess the effectiveness of VR-based interventions for AA. OBJECTIVE This protocol aims to provide a comprehensive description of the design and methodology of the STEPS trial. METHODS STEPS is a clinical, randomised, assessor-blinded, parallel-group superiority trial. A total of 140 participants will be allocated to receive either VR-based social cognitive training (VRSCT) + treatment as usual (TAU), or TAU alone. The experimental group will receive 12 weekly, one-hour sessions of VRSCT, aiming at improving psychosocial functioning and social cognition through exposure to virtual social environments. The intervention comprises three core modules: Emotions, Social Understanding, and Complex Social Interactions. The exact content and duration of TAU received by each participant will be mapped and documented upon trial completion. Assessments will be conducted at baseline, at cessation of the intervention (3 months post-baseline), and at 6 months post-baseline. RESULTS The trial is currently recruiting participants. The first participant was enrolled in May 2024. Completion of recruitment is expected in January 2026. Data analysis is expected to commence in summer 2026, following the final six-month follow-up assessment. Results are anticipated by fall 2026 and will be disseminated at international conferences and through peer-reviewed publications. CONCLUSIONS To our knowledge, STEPS is the hitherto largest randomised clinical trial globally investigating the effect of VRSCT for AA. The results of this innovative intervention approach may significantly advance research in the field of autism. VRSCT holds potential to improve psychosocial functioning, quality of life, co-occurring clinical symptoms and reduce social cognitive deficits in AA. Establishing evidence-based interventions is crucial for addressing the debilitating psychosocial challenges faced by this population, especially considering the absence of established gold-standard treatments. CLINICALTRIAL Registered at ClinicalTrials.gov (ID: NCT06438536). https://clinicaltrials.gov/study/NCT06438536?term=NCT06438536&rank=1
- 21 February 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Effect of Virtual Reality-based Social Cognitive Training for Autistic Adults: A Study Protocol for STEPS (Social Cognitive Training Enhancing Pro-functional Skills), a Randomised Clinical Trial (Preprint)
BACKGROUND Autistic adults (AA) constitute a growing and largely overlooked population with limited clinical and research resources. Social cognitive impairments are key deficits faced by this population, significantly impacting social interactions, educational and vocational functioning, and quality of life. Interventions targeting social cognition in AA, have shown promising results. Recent studies investigating the effect of virtual reality (VR)-based interventions for AA have provided preliminary evidence supporting the feasibility and effectiveness of utilizing this innovative technology. These studies indicate that VR-interventions can enhance functional and social skills and improve specific neurocognitive and social cognitive functions. However, large scale, randomised, clinical trials are urgently needed to fully assess the effectiveness of VR-based interventions for AA. OBJECTIVE This protocol aims to provide a comprehensive description of the design and methodology of the STEPS trial. METHODS STEPS is a clinical, randomised, assessor-blinded, parallel-group superiority trial. A total of 140 participants will be allocated to receive either VR-based social cognitive training (VRSCT) + treatment as usual (TAU), or TAU alone. The experimental group will receive 12 weekly, one-hour sessions of VRSCT, aiming at improving psychosocial functioning and social cognition through exposure to virtual social environments. The intervention comprises three core modules: Emotions, Social Understanding, and Complex Social Interactions. The exact content and duration of TAU received by each participant will be mapped and documented upon trial completion. Assessments will be conducted at baseline, at cessation of the intervention (3 months post-baseline), and at 6 months post-baseline. RESULTS The trial is currently recruiting participants. The first participant was enrolled in May 2024. Completion of recruitment is expected in January 2026. Data analysis is expected to commence in summer 2026, following the final six-month follow-up assessment. Results are anticipated by fall 2026 and will be disseminated at international conferences and through peer-reviewed publications. CONCLUSIONS To our knowledge, STEPS is the hitherto largest randomised clinical trial globally investigating the effect of VRSCT for AA. The results of this innovative intervention approach may significantly advance research in the field of autism. VRSCT holds potential to improve psychosocial functioning, quality of life, co-occurring clinical symptoms and reduce social cognitive deficits in AA. Establishing evidence-based interventions is crucial for addressing the debilitating psychosocial challenges faced by this population, especially considering the absence of established gold-standard treatments. CLINICALTRIAL Registered at ClinicalTrials.gov (ID: NCT06438536). https://clinicaltrials.gov/study/NCT06438536?term=NCT06438536&rank=1
- Open Access
- 28 March 2023
- Published by Springer Nature in BMC Psychiatry
- Vol. 23 (1) , 1-9
Protocol for the development and testing of the schiZotypy Autism Questionnaire (ZAQ) in adults: a new screening tool to discriminate autism spectrum disorder from schizotypal disorder
Background: Autism spectrum disorder (ASD) and schizotypal disorder (SD) both have a heterogenous presentation, with significant overlaps in symptoms and behaviour. Due to elevated recognition and knowledge of ASD worldwide, there is a growing rate of referrals from primary health professionals to specialised units. At all levels of assessment, the differential diagnostic considerations between ASD and SD exert major challenges for clinicians. Although several validated screening questionnaires exist for ASD and SD, none have differential diagnostic properties. Accordingly, in this study, we aim to develop a new screening questionnaire, the schiZotypy Autism Questionnaire (ZAQ), which provides a combined screening for both conditions, while also indicating the relative likelihood of each. Methods: We aim to test 200 autistic patients and 100 schizotypy patients recruited from specialised psychiatric clinics and 200 controls from the general population (Phase 1). The results from ZAQ will be compared to the clinical diagnoses from interdisciplinary teams at specialised psychiatric clinics. After this initial testing phase, the ZAQ will be validated in an independent sample (Phase 2). Conclusions: The aim of the study is to investigate the discriminative properties (ASD vs. SD), diagnostic accuracy, and validity of the schiZotypy Autism Questionnaire (ZAQ). Funding: Funding was provided by Psychiatric Centre Glostrup, Copenhagen Denmark, Sofiefonden (Grant number: FID4107425), Trygfonden (Grant number:153588), Takeda Pharma. Trial registration: Clinical Trials, NCT05213286, Registered 28 January 2022, clinicaltrials.gov/ct2/show/NCT05213286?cond = RAADS&draw = 2&rank = 1.
- 28 March 2023
- Published by Springer Nature in BMC Psychiatry
- Vol. 23 (1) , 1-9
Open AccessProtocol for the development and testing of the schiZotypy Autism Questionnaire (ZAQ) in adults: a new screening tool to discriminate autism spectrum disorder from schizotypal disorder
Background: Autism spectrum disorder (ASD) and schizotypal disorder (SD) both have a heterogenous presentation, with significant overlaps in symptoms and behaviour. Due to elevated recognition and knowledge of ASD worldwide, there is a growing rate of referrals from primary health professionals to specialised units. At all levels of assessment, the differential diagnostic considerations between ASD and SD exert major challenges for clinicians. Although several validated screening questionnaires exist for ASD and SD, none have differential diagnostic properties. Accordingly, in this study, we aim to develop a new screening questionnaire, the schiZotypy Autism Questionnaire (ZAQ), which provides a combined screening for both conditions, while also indicating the relative likelihood of each. Methods: We aim to test 200 autistic patients and 100 schizotypy patients recruited from specialised psychiatric clinics and 200 controls from the general population (Phase 1). The results from ZAQ will be compared to the clinical diagnoses from interdisciplinary teams at specialised psychiatric clinics. After this initial testing phase, the ZAQ will be validated in an independent sample (Phase 2). Conclusions: The aim of the study is to investigate the discriminative properties (ASD vs. SD), diagnostic accuracy, and validity of the schiZotypy Autism Questionnaire (ZAQ). Funding: Funding was provided by Psychiatric Centre Glostrup, Copenhagen Denmark, Sofiefonden (Grant number: FID4107425), Trygfonden (Grant number:153588), Takeda Pharma. Trial registration: Clinical Trials, NCT05213286, Registered 28 January 2022, clinicaltrials.gov/ct2/show/NCT05213286?cond = RAADS&draw = 2&rank = 1.